Business
Voluntary Delisting from OTCQB Market
Voluntary Delisting from OTCQB Market.
About this update from Poolbeg Pharma Plc
[{"type":"text","content":"\n\nPoolbeg Pharma plc\n \nVoluntary Delisting from OTCQB Market\n \n26 July 2024- Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it is voluntarily delisting its ordinary shares (\"Ordinary Shares\") from trading on the OTCQB Market due to low trading volume and the associated administrative requirements. The Company's last day of trading on the OTCQB Market will be Monday 29 July 2024.\nPoolbeg will retain its listing on the London Stock Exchange's AIM Market under its existing ticker \"POLB\". The delisting from the OTCQB market will have no impact on Poolbeg's Ordinary Shares, which will continue to trade on the AIM Market.\nPoolbeg reaffirms its ambitions to be dual listed on a national securities exchange in the US, such as Nasdaq, subject to meeting their listing requirements at the appropriate time.\n \nEnquiries \n \n\n\n\n\nPoolbeg Pharma Plc \nJeremy Skillington, CEO \nIan O'Connell, CFO \n \n\n\n+44 (0) 207 183 1499 \n\n\n\n\nCavendish Capital Markets Ltd (Nominated Adviser & Joint Broker) \nGeoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM) \n \n\n\n+44 (0) 207 220 0500 \n\n\n\n\nShore Capital Stockbrokers Ltd (Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory), Malachy McEntyre, Isobel Jones (Corporate Broking)\n \n\n\n+44 (0) 207 408 4090\n\n\n\n\nJ&E Davy (Joint Broker) \nAnthony Farrell, Niall Gilchrist \n \n\n\n+353 (0) 1 679 6363 \n\n\n\n\nOptimum Strategic Communications \nNick Bastin, Vici Rabbetts, Elena Bates \n \n\n\n+44 (0) 208 078 4357 \[email protected] \n\n\n\n\n \nAbout Poolbeg Pharma \n \nPoolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving signifi...